'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
1. Martin Shkreli predicts a 90% drop for INMB shares. 2. Shkreli cites weak Phase 1 trial data as a major concern. 3. Recent enthusiasm followed INMB's 44% surge relating to XPro1595. 4. BMF Reports supports Shkreli's critique of INMB's scientific integrity. 5. INMB shares fell by 15% on Friday ahead of Shkreli's post.